There are 2789 resources available
274P - Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Efficacy and safety results of the advanced breast cancer (ABC) patients (pts) cohort of the MOVIE study
Presenter: Thibault De La Motte Rouge
Session: ePoster Display
276P - Dalpiciclib, a novel CDK4/6 inhibitor, combined with pyrotinib for HER2+ advanced breast cancer: Interim results of a phase II trial
Presenter: Min Yan
Session: ePoster Display
277P - Phase II randomized study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea in patients with HR-positive and HER2-negative advanced breast cancer (MERMAID) WJOG11318B
Presenter: Hiroko Masuda
Session: ePoster Display
278P - Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients
Presenter: Sergei Krasny
Session: ePoster Display
279P - Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
Presenter: Cristina Saura Manich
Session: ePoster Display
280P - Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial
Presenter: Rupert Bartsch
Session: ePoster Display
281P - Prognostic impact of immune interactions in HER2+ and triple-negative breast cancer brain metastases
Presenter: Gaia Griguolo
Session: ePoster Display
282P - Methylthioadenosine phosphorylase (MTAP) genomic loss in ERBB2 amplified (amp) and mutated (mut) (ERBB2+) metastatic breast cancer (MBC)
Presenter: Abirami Sivapiragasam
Session: ePoster Display